School of Medicine


Showing 31-40 of 60 Results

  • Y. Joyce Liao, MD, PhD

    Y. Joyce Liao, MD, PhD

    Stanford Medicine Professor of Ophthalmology and Professor of Neurology and Neurological Sciences

    Current Research and Scholarly InterestsIschemic optic neuropathy
    Stem cell transplantation
    Optic neuropathy
    Optic neuritis
    Eye movement disorders
    Reading
    Parkinson's disease
    Multiple sclerosis

  • Wendy Liu, MD, PhD

    Wendy Liu, MD, PhD

    Assistant Professor of Ophthalmology

    Current Research and Scholarly InterestsDr. Liu's research interests include the role of mechanosensation in the eye as it relates to the pathophysiology of glaucoma, with the goal of finding new druggable targets in glaucoma treatment.

  • Anson Lowe

    Anson Lowe

    Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus

    Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.

  • Ying Lu

    Ying Lu

    Professor of Biomedical Data Science and, by courtesy, of Epidemiology

    Current Research and Scholarly InterestsBiostatistics, clinical trials, statistical evaluation of medical diagnostic tests, radiology, osteoporosis, meta-analysis, medical decision making

  • Ruben Y. Luo

    Ruben Y. Luo

    Assistant Professor of Pathology

    Current Research and Scholarly InterestsApply top-down mass spectrometry and label-free immunoassay to the study and utilization of biomarker proteoforms in clinical diagnosis.

  • Kenneth Mahaffey

    Kenneth Mahaffey

    Professor of Medicine (Cardiovascular Medicine)

    BioClinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;

    Research Focus:

    My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.

    Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB

    Professional Training:

    1985 Stanford University, BS Chemistry
    1989 University of Washington, MD
    1993 University of Arizona, Internship/Residency/Chief Residency
    1996 Duke University, Fellowship in Cardiology
    1996 Duke University, Faculty in Cardiology
    2013 Stanford University, Faculty Cardiovascular Medicine

  • Jessica Patricia Meyer

    Jessica Patricia Meyer

    Assistant Manager, Workforce Development, Translational Research Operations

    Current Role at StanfordSpectrum is the Stanford Center for Clinical and Translational Research and Education—bridging each stage of medical innovation from basic research to public health. Within Translational Workforce Development, I manage multiple education programs with over 100 education and training events per year including the Intensive Course in Clinical Research, Essentials of Clinical Research, KL2 Mentored Career Development Program, Research Career Accelerator Program, the Clinical Research Operations Program and the Stanford Program on Rigor and Reproducibility. These programs are designed to train seasoned and early investigators, students and staff, on study design, operations, regulations, ethics, data management, and many other facets of clinical research.

    Programs & Events:
    - Patient Advocacy Training in Health Sciences (PATHS)
    - Spectrum KL2 Mentored Career Development Program
    - Spectrum TL1 Training Program
    - Research Career Accelerator Program (ReCAP)
    - Stanford Clinical Research Operations Program & Certification
    - Essentials of Clinical Research at Stanford (EoCR)
    - Intensive Course in Clinical Research: Study Design and Performance (ICCR)
    - Stanford Program on Research Rigor and Reproducibility (SPORR)
    - Stanford K-Fest
    - Principles and Practices of Early-Phase Translational Research: A 3-day Course
    - USPTO "Intellectual Property and Entrepreneurship in Medical Devices" Conference
    - Continuing Education Provider, Board of Registered Nursing

  • Carlos Milla

    Carlos Milla

    Professor of Pediatrics (Pulmonary Medicine) and, by courtesy, of Medicine (Pulmonary and Critical Care Medicine)

    Current Research and Scholarly InterestsAt Stanford University I developed and currently direct the CF Translational Research Center. The overarching goal of the center is to provide the groundwork to streamline, accelerate, and promote the translation of basic discoveries into effective therapies and interventions to benefit patients affected by cystic fibrosis. My laboratory group currently has three main lines of investigation: respiratory cell biology in CF; remote biochemical monitoring; and lung physiology in young children.

  • Daria Mochly-Rosen

    Daria Mochly-Rosen

    George D. Smith Professor of Translational Medicine

    Current Research and Scholarly InterestsTwo areas: 1. Using rationally-designed peptide inhibitors to study protein-protein interactions in cell signaling. Focus: protein kinase C in heart and large GTPases regulating mitochondrial dynamics in neurodegdenration. 2. Using small molecules (identified in a high throughput screens and synthetic chemistry) as activators and inhibitors of aldehyde dehydrogenases, a family of detoxifying enzymes, and glucose-6-phoshate dehydrogenase, in normal cells and in models of human diseases.